Table 1 Trials' characteristics.
Authors | Pts | Phase | Experimental Arm | Primary End-Point | Secondary End-Point | Female (%) | Rectal (%) | Adjuvant (%) |
|---|---|---|---|---|---|---|---|---|
Hurwitz et al[2] | 813 | III | IFL+Beva | OS | PFS, ORR, DR, QoL | *40% | 21% | 26% |
Hurwitz et al[3] | 210 | III | FU/LV+Beva | OS | PFS, ORR, DR | 39% | 29% | - |
Saltz et al[6] | 1,400 | III | FOLFOX/XELOX+Beva | PFS | PFS, OS, RR, DR, TTF | 42% | 26% | 24% |
Kabbinavar et al[4] | 104 | II | FU/LV+Beva | TTP, RR | OS, DR | 43% | - | 19% |
Kabbinavar et al[23] | 209 | II | FU/LV+Beva | OS | PFS, ORR, DR, QoL | 46% | 19% | 20% |